FAVIPIRAVIR
Favipiravir-RTP binds to and inhibits RNA-dependent RNA polymerase (RdRp), which ultimately prevents viral transcription and replication. Favipiravir is an antiviral medication that belongs to the class of RNA polymerase inhibitors. It works by inhibiting the replication of RNA viruses, including influenza viruses and certain RNA viruses that cause respiratory infections.Favipiravir is primarily indicated for the treatment of influenza, particularly in cases where the virus is resistant to other antiviral medications. It has also shown effectiveness against certain other RNA viruses, making it a potential treatment for emerging viral infections. It is indicated among adults (age equal or greater then18years) in the treatment of mild to moderate cases of covid-19.
-The dosage of favipiravir may vary depending on the specific condition being treated and the severity of the infection. It is typically administered orally. It is crucial to follow the prescribed dosage and duration as directed by a healthcare professional. - Oral; 1800mg twice daily for first day than 800mg twice daily for maximum period of 14 days.
-Favipiravir is contraindicated in individuals with a known hypersensitivity to the drug. Pregnant or breastfeeding women and individuals with severe renal impairment may also be advised against its use. -Pregnancy, lactating women, severe renal impairment, severe hepatic impairment, hypersensitivity to active substance.
-Special precautions should be taken in patients with a history of renal disorders, as favipiravir is primarily excreted through the kidneys. Close monitoring of renal function is recommended during the course of treatment. -Paediatric: Not studied in pediatrics age group. Pregnancy: Contraindicated. Lactation: Contraindicated. Elderly: use with caution.
-Common side effects of favipiravir may include gastrointestinal discomfort, nausea, vomiting, and elevated levels of uric acid. Serious side effects are rare but may include allergic reactions and liver function abnormalities. Any unusual symptoms should be reported to a healthcare professional promptly. -Increased blood uric acid level, diarrhea, decrease of neutrophil count, increased SGOT, increased SGPT.
-Favipiravir may interact with certain medications, including those metabolized by the liver. It is essential to inform the healthcare provider about all medications, supplements, and herbal products being taken to avoid potential interactions. -Pyrazinamide, repaglinide, theophylline, sulindac, famciclovir.
